These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 6198228)
1. Immunogenicity of recombinant DNA human insulin. Fineberg SE; Galloway JA; Fineberg NS; Rathbun MJ; Hufferd S Diabetologia; 1983 Dec; 25(6):465-9. PubMed ID: 6198228 [TBL] [Abstract][Full Text] [Related]
2. Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Fineberg SE; Galloway JA; Fineberg NS; Goldman J Diabetes; 1983 Jul; 32(7):592-9. PubMed ID: 6345238 [TBL] [Abstract][Full Text] [Related]
3. Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin. Kurtz AB; Matthews JA; Mustaffa BE; Daggett PR; Nabarro JD Diabetologia; 1980; 18(2):147-50. PubMed ID: 6988274 [TBL] [Abstract][Full Text] [Related]
4. A double-blind crossover trial comparing human insulin (recombinant DNA) with animal insulins in the treatment of previously insulin-treated diabetic patients. Clark AJ; Wiles PG; Leiper JM; Knight G; Adeniyl-Jones RO; Watkins PJ; Ward JD; MacCuish AC; Keen H; Jones RH Diabetes Care; 1982; 5 Suppl 2():129-34. PubMed ID: 6765523 [TBL] [Abstract][Full Text] [Related]
5. A fifteen-month double-blind cross-over study of the efficacy and antigenicity of human and pork insulins. Home PD; Mann NP; Hutchison AS; Park R; Walford S; Murphy M; Reeves WG Diabet Med; 1984 Jul; 1(2):93-8. PubMed ID: 6086002 [TBL] [Abstract][Full Text] [Related]
6. Immunologic improvement resulting from the transfer of animal insulin-treated diabetic subjects to human insulin (recombinant DNA). Fineberg SE; Galloway JA; Fineberg NS; Rathbun MJ Diabetes Care; 1982; 5 Suppl 2():107-13. PubMed ID: 6765519 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Schernthaner G; Borkenstein M; Fink M; Mayr WR; Menzel J; Schober E Diabetes Care; 1983; 6 Suppl 1():43-8. PubMed ID: 6343038 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of highly purified porcine and human insulins in diabetic patients with high titers of insulin antibody. Lam HC; Ho LT; Tang KT; Wang LM; Kwok CF; Liu YF; Hsiao LJ; Li SH Taiwan Yi Xue Hui Za Zhi; 1989 Apr; 88(4):346-51. PubMed ID: 2677227 [TBL] [Abstract][Full Text] [Related]
9. The production and characteristics of anti-insulin, anti-A-component and anti-proinsulin antibodies in patients treated with monocomponent or conventional insulin. Kawazu S; Kanazawa Y; Miki E; Hayashi M; Sando H; Kajinuma H; Iwamoto Y; Akanuma Y; Kosaka K Acta Diabetol Lat; 1979; 16(4):339-51. PubMed ID: 399151 [TBL] [Abstract][Full Text] [Related]
10. Circulating insulin antibodies during therapy with highly purified neutrally buffered insulins including desphe insulins. Report of a prospective study with 40 cases. Kühnau J; Rüdiger H; Goetz K Exp Clin Endocrinol; 1984 Apr; 83(2):161-7. PubMed ID: 6373318 [TBL] [Abstract][Full Text] [Related]
11. Recognition of human insulin in vitro by T cells from subjects treated with animal insulins. Nell LJ; Virta VJ; Thomas JW J Clin Invest; 1985 Dec; 76(6):2070-7. PubMed ID: 2416775 [TBL] [Abstract][Full Text] [Related]
12. Aspects of humoral immunity in a prospective study of Type I (insulin-dependent) diabetic subjects treated with insulins of different purity. Iavicoli M; Ventriglia L; Di Mario U; Galfo C; Andreani D Diabetologia; 1983 Jan; 24(1):26-9. PubMed ID: 6186559 [TBL] [Abstract][Full Text] [Related]
13. [Immunogenicity of semisynthetic human insulin Novo--five year prospective studies]. Rogala H; Czyzyk A; Lawecki J Pol Arch Med Wewn; 1993 Jun; 89(6):492-8. PubMed ID: 8415211 [TBL] [Abstract][Full Text] [Related]
14. Human insulin. Raptis S; Dimitriadis G Clin Physiol Biochem; 1985; 3(1):29-42. PubMed ID: 3888492 [TBL] [Abstract][Full Text] [Related]
15. Diabetic control in patients treated with once or twice-daily insulin injections, including a comparison of conventional beef and highly purified pork insulins. Gray RS; Borsey DQ; Fraser DM; Kurtz AB; Rainbow S; Smith AF; Duncan LJ; Clarke BF Diabetologia; 1981 Sep; 21(3):206-10. PubMed ID: 7028552 [TBL] [Abstract][Full Text] [Related]
16. The immunogenicity of new insulins. Deckert T Diabetes; 1985 Jun; 34 Suppl 2():94-6. PubMed ID: 3888748 [TBL] [Abstract][Full Text] [Related]
17. Subpopulations of antibodies directed against evolutionarily conserved regions of the insulin molecule in insulin-treated patients. Karlsson F; Harrison LC; Kahn CR; Itin A; Roth J Diabetologia; 1982 Dec; 23(6):488-93. PubMed ID: 6759274 [TBL] [Abstract][Full Text] [Related]
18. Insulin antibodies in the maternal and foetal circulation of pregnant diabetic women treated with human insulin of recombinant DNA origin. Leiper JM; Fineberg SE; Lunan CB; MacCuish AC Diabetes Res; 1984 Jul; 1(2):75-81. PubMed ID: 6397289 [TBL] [Abstract][Full Text] [Related]
19. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Fireman P; Fineberg SE; Galloway JA Diabetes Care; 1982; 5 Suppl 2():119-25. PubMed ID: 6765521 [TBL] [Abstract][Full Text] [Related]
20. Antigenicity of "monocomponent" pork insulin in diabetic subjects. Yue DK; Turtle JR Diabetes; 1975 Jul; 24(7):625-32. PubMed ID: 1171804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]